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Introduction. Antiepileptic drugs (AEDs) are used to treat different conditions in elderly patients and are among the drug classes
most susceptible to be involved in drug-drug interactions (DDI). The aim of the study was to describe and compare use of AEDs
between home care service and nursing home patients, as these patients are not included in nationwide databases of drug utilization.
In the combined population, we investigate DDI of AEDs with other central nervous system- (CNS-) active drugs and DDIs
involving AEDs in general.Materials andMethods. Point-prevalence study of Norwegian patients in home care services and nursing
homes in 2009. At the patient level, we screened for different DDIs involving AEDs. Results. In total, 882 patients (7.8%) of 11,254
patients used AEDs and number of users did not differ between home care services and nursing homes (8.2% versus 7.7%). In the
combined population, we identified 436 potential DDIs in 45% of the patients. Conclusions. In a large population of elderly, home
care service and nursing home patients do not differ with respect to exposure of AEDs but use more AEDs as compared to the
general population of similar age.The risk of DDIs with AEDs and other CNS-active drugs should be taken into consideration and
individual clinical evaluations are assessed in this population.
1. Introduction
Due to their complex pharmacokinetic properties, antiepilep-
tic drugs (AEDs) are among the drug classes most susceptible
to be involved in drug-drug interactions (DDIs). In addition,
the risk of pharmacodynamic interactions is augmented by
concomitant prescribing with other central nervous system-
(CNS-) active drugs [1]. The use of AEDs has increased
during the last decade [2–4] because, in addition to treating
epilepsy, AEDs are used to treat numerous other diseases
and symptoms such as neuropathic pain (e.g., gabapentin and
pregabalin), bipolar disease (e.g., lamotrigine), and migraine
(e.g., valproate and topiramate) [2, 5–7].
Ageing in itself causes a reduction in hepatic and
renal function, which subsequently altered blood flow,
drug-protein binding, volume of distribution, clearance, and
elimination half-life [8]. Pharmacokinetic considerations are
important in this age group [9], particularly since many
users of AEDs are older patients ≥65 years with a range of
comorbidities and polypharmacy. This increases the risk for
unintended pharmacokinetic and dynamic DDIs in this age
group.
During the past 15 years, automatic drug dispensing or
multidose drug dispensing, where patients receive medicines
in small, prepackaged, and labelled plastic bags, has become
a major dispensing method in Norway. The error rate of this
automatic system is highly favourable compared to manual
dispensing resulting in increased patient safety. Still, the fre-
quencies of drug-related problems, that is, pharmacokinetic
DDIs, are of concern [10].
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Few studies have investigated DDIs involving AEDs in
specialized health care settings, such as home care services
and nursing homes. With more than 160,000 patients receiv-
ing home care services and about 43,000 patients in nursing
homes, these settings constitute the largest health care service
level in Norway. Patients receiving home care services are
visited by a health care professional, that is, nurse, up to
several times a day depending on caring needs [11]. Cognitive
impairment affects about 30% of the patients. Patients in
nursing homes are considered evenmore frail asmost of them
suffer from multiple chronic comorbid conditions, and 80%
of these patients have cognitive impairment [12]. To improve
the quality of drug therapy for older patients in these settings,
it is important to conduct pharmacoepidemiological or drug
utilization studies focusing on the identification of potentially
inappropriate medications and potential DDIs.
The aim of the study was to describe and compare use of
AEDs between home care service and nursing home patients,
as these patients are not included in nationwide databases of
drug utilization. Furthermore, in the combined population,
we investigate potential DDIs involving AEDs and other
central nervous system- (CNS-) active drugs and DDIs
involving AEDs in general. This is an important concern
for prescribers and clinical pharmacists when reviewing the
appropriateness of drug therapy in the elderly.
2. Materials and Methods
2.1. Study Population. In this point-prevalence study, we
received information about patients’ drug use from Farmaka
AS (Alliance Health), one of three suppliers of multidose
dispensed drugs in Norway, on September 9th 2009. The
company market share was ca. thirty percent of all multidose
dispensed drug patients in home care services and nursing
homes. The patients lived in all parts of Norway, except the
less populated northern region. This is a unique source with
regard to details of the prescribed drug, strength, dosage, for-
mulation, and patient demographics, that is, not extractable
from the Norwegian prescription database (NorPD) [13].
Furthermore, the NorPD does not reveal whether a patient
receives home care services or not or any drug information
about nursing home patients.
We included only patients aged 65 years and older and
using ≥1 drug and those who received home care services or
lived in nursing homes. For each patient, the following vari-
ables were provided: age, gender, setting (home care service
or nursing home), and all regular multidose dispensed drugs
(drug name, strength, formulation, and dosage). Consecutive
running numbers providing anonymous data replaced the
patients’ social security numbers. We excluded patients if
information on gender was missing (𝑛 = 47) and if they
only received drug formulations not dispensed as multidose
dispensed drugs (i.e., inhalers, ointments, mixtures, suppos-
itories, and injectables; 𝑛 = 217), medications exclusively
prescribed “as required,” herbal remedies, and medications
with unclear dosage (𝑛 = 34). All drugs were coded according
to WHO’s Anatomical Therapeutic Chemical (ATC) classifi-
cation system [14].
2.2. Use of Antiepileptic Drugs. Wecompared the use of AEDs
on the substance level between home care service and nursing
homes patients by means of percentages of AEDs users and
whether patients differed with respect to the use of older
versus newer AEDs. AEDs approved before 1990 are regarded
as the older drugs, namely, carbamazepine, ethosuximide,
phenobarbital, phenytoin, primidone, and valproic acid and
the benzodiazepines clobazam, clonazepam, and diazepam,
whereas all drugs approved after 1990 are defined as the newer
drugs [15]. We defined patients using one or more AEDs as
AED users.
2.3. Drug-Drug Interactions Involving AEDs and CNS-Active
Drugs. CNS-active drugs included opioid analgesics (N02A),
antipsychotics (N05A), anxiolytics (N05B), hypnotics and
sedatives (N05C), and antidepressants (N06A). Patients using
one or more CNS-active drugs were defined as CNS-active
drug users. Concomitant prescribing of CNS-active drugs
with AEDs was analyzed at the patient level. We also con-
sulted Norwegian and Danish drug interaction databases
for clinical effects and potential consequences of combining
AED with other CNS-active drugs. The Norwegian drug
interaction database (DRUID) classifies DDIs according to
a three-point severity scale: A, should not be combined, B,
take precautions, and C, of academic interest [16]. According
to this classification, we screened the 882 AED users’ drug
lists for frequencies of DDIs involving AEDs. In addition, we
searched the Danish interaction database for clinical effects
of DDIs [17].
2.4. Ethics and Approvals. The Norwegian Social Science
Data Services approved data collection from the supplier
given that they were anonymized. Therefore, the Regional
Committee forMedical andHealthResearchEthics presented
no objections regarding the study design and concluded that
committee clearance was not required.
2.5. Statistical Analysis. Student’s 𝑡-test was applied to com-
pare means (continuous data: age and number of drugs used)
and 𝜒2 test was used to compare proportions (categorical
data: gender, type of care (home care services versus nursing
homes), and older versus newer AEDs). Logistic regression
was performed to examine the impact of different factors
on the likelihood that older patients in home care service
and nursing home were using AEDs (dependent categorical
variable: nonuser of AED = 0; user of AED = 1). The
model included four independent variables (gender, age, total
number of drugs, and setting). We report effect estimates of
the impact of settings as prevalence odds ratio (OR) with
95% confidence interval (CI) and 𝑝 < 0.05 significant level.
Analyses were performed using SPSS Version 21 (SPSS, Inc.,
Chicago, IL, USA).
3. Results
3.1. Population Characteristics. The study population com-
prised 11,254 patients ≥65 years: 8,268 in home care service
(69% women) and 2,986 in nursing homes (72% women).
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Table 1: Patient characteristics, total use of multidose dispensed drugs, and distribution of antiepileptic drugs by gender among elderly
patients ≥65 years in nursing homes and home care services (𝑛 = 11254).
Total group Nursing homes Home care services
Total Men Women Total Men Women
Population
≥65 years 11254 100 2986 100 843 28.2 2143 71.8 8268 100 2566 31.0 5702 69.0
Non-AED users
𝑛, % 10372 92.1 2741 91.8 753 89.3 1988 92.8 7631 92.3 2315 90.2 5316 93.2
Age (M), SD 84.0 7.2 85.7 7.1 83.4 7.3 86.6 6.8 83.4 7.1 81.6 7.4 84.1 6.8
Drugs (M), SD 5.6 2.5 5.6 2.7 5.6 5.6 5.6 2.7 5.6 2.4 5.4 2.4 5.6 2.5
AED users
𝑛, % 882 7.8 245 8.2 90 10.7 155 7.2 637 7.7 251 9.8 386 6.8
Age (M), SD 79.0 8.2 81.0 8.3 78.9 7.1 82.3 8.8 78.2 8.1 76.4 7.9 79.4 8.0
Drugs (M), SD 7.0 2.8 7.3 3.0 7.1 2.8 7.3 3.1 7.0 2.7 6.6 2.7 7.2 2.6
AED, antiepileptic drug; M, mean; SD, standard deviation.
Table 2: Antiepileptic drug use among patients (𝑛 = 882) in home care services (HCS) and nursing homes. The association (odds ratio, OR)
and 95% confidence interval (CI) for use of the drugs, adjusted for patients’ age, gender, and total number of drugs used in different settings
(home care service used as reference).
Drug Home care services (𝑛 = 637) Nursing homes (𝑛 = 245) All patients (𝑛 = 882) OR CI
𝑛 % 𝑛 % 𝑛 %
Carbamazepine 134 21.0 55 22.4 189 21.4 0.88 0.61–1.26
Pregabalin 95 14.9 50 20.4 145 16.4 0.80 0.54–1.18
Lamotrigine 102 16.0 32 13.1 134 15.2 1.15 0.74–1.79
Gabapentin 104 16.3 29 11.8 133 15.1 1.72 1.09–2.70
Valproate 66 10.4 27 11.0 93 10.5 0.78 0.48–1.26
Clonazepam 60 9.4 27 11.0 87 9.9 0.79 0.49–1.29
Phenobarbital 48 7.5 15 6.1 63 7.1 1.26 0.68–2.31
Levetiracetam 49 7.7 12 4.9 61 6.9 1.46 0.76–2.81
Phenytoin 29 4.6 10 4.1 39 4.4 1.08 0.51–3.99
Oxcarbazepine 11 1.7 10 4.1 21 2.4 0.36 0.15–0.86
Topiramate 4 0.6 1 0.4 5 0.6 1.29 0.14–11.83
Zonisamide 3 0.5 0 0 3 0.3 — —
Primidone∗ 1 0.2 0 0 1 0.1 — —
Total 706 268 974∗∗
∗Not marketed in Norwegian. ∗∗Some patients used more than one antiepileptic drug. OR, odds ratio; CI, confidence interval (95%).
On average, patients in home care service were younger than
those in nursing homes (83.0 versus 85.3 years; 𝑝 < 0.001).
Women were generally older than men in both home care
services (83.8 versus 81.1; 𝑝 < 0.001) and nursing homes (86.3
versus 82.9; 𝑝 < 0.001). Information regarding 63,936 drugs
was available, and patients in both settings received amean of
5.7 regularly dispensed drugs. In the total study population,
women received 5.7 drugs and men received 5.5 drugs.
3.2. Use of Antiepileptic Drugs. In total, 882 patients (7.8%)
used altogether 974 AEDs, with no significant difference
between home care services and nursing homes (8.2% versus
7.7%; 𝑝 = 0.383). Of the 882 patients, 801 (90.8%) were
monotherapy users, 70 patients (7.9%) used two AEDs, and
11 patients (1.2%) used three AEDs. We identified 13 different
AEDs in use, where carbamazepine, pregabalin, lamotrigine,
and gabapentin were the most commonly used, accounting
for more than 60% of the total AED consumption (see
Table 2). Pregabalin and gabapentin were used by 278 (31.5%)
of 882 patients. Two AEDs differed in use between settings;
gabapentin was more frequently prescribed in home care
services (OR: 1.72; CI: 1.09–2.70), while oxcarbazepine was
more commonly prescribed in nursing homes (OR: 0.36;
CI: 0.15–0.86). When comparing older versus newer AEDs,
we observed no significant differences between home care
services andnursing homes (olderAEDs: 50.5%versus 54.3%;
𝑝 = 0.320). However, in the combined population, men
used older AEDsmore frequently than women (56.6% versus
48.4%; 𝑝 = 0.018); patients taking AEDs were younger than
nonusers (79.0 versus 84.0 years; 𝑝 < 0.001) and also used
more drugs (7.0 versus 5.6 drugs; 𝑝 < 0.001, Table 1).
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3.3. Drug-Drug Interactions Involving AEDs and CNS-Active
Drugs. In the combined population, 436 different DDIs were
present in 45% of the patients using AED. We identified
79 different pharmacokinetic interactions involving AEDs
drugs with other CNS-active drugs (Table 3). Patients using
AEDs were more frequently prescribed CNS-active drugs
compared to non-AEDs users (9.2% versus 6.0%; 𝑝 < 0.001),
and this combination was more often prescribed to men
than women (12.2% versus 8.1%; 𝑝 < 0.001). Antidepressants
(6.6%), antipsychotics (3.0%), and opioids (2.3%) were all
more frequently prescribed among users of AEDs. Seventy-
nine patients (9.0%) were prescribed AEDs concomitantly
with opioids (N02A).
3.4. Antiepileptic Drugs Involved in Other Drug-Drug Inter-
actions. We identified 357 other potential DDIs involving
AEDs. Of these, also here 79 were pharmacokinetic interac-
tions, 265 were pharmacodynamics interactions, and 13 were
classified as other (Table 4). Four of the identified AEDs,
carbamazepine, phenobarbital, phenytoin, and valproic acid,
are habitually involved in pharmacokinetic DDIs (𝑛 = 151),
while pregabalin and gabapentin are more prone to pharma-
codynamics interactions (𝑛 = 206). Simvastatin (𝑛 = 35) and
zopiclone (𝑛 = 109) were the drugsmost prevalently involved
in pharmacokinetic and dynamic interactions, respectively.
4. Discussion
In this large study of home care service and nursing home
patients, we identified similar use of AEDs among patients
in both settings but higher use as compared to the general
older Norwegian population [13]. The use of older versus
newer AEDs did not vary significantly between home care
services and nursing homes. The most commonly used AED
was carbamazepine, which is defined among the older drugs.
Newer AEDs, however, should in many cases be preferred, as
they have a lower potential for causing enzyme induction and
inhibition; they usually have more simple pharmacokinetic
properties and rarely cause serious adverse effects [6]. In
nearly half of all patients, AEDs were involved in potential
DDIs. This highlights the importance of awareness of DDIs
to identify and to monitor potential harmful effects in the
individual patient among the elderly.
4.1. Total Drug Consumption. The average use of 5.7 mul-
tidose dispensed drugs in elderly patients in home care
services and nursing homes reflects similar comorbidity
between the two settings. The association between polyphar-
macy (≥5 drugs), use of inappropriate drugs, and adverse
drug reactions is well known and calls for attention when
changing drug therapy in frail elderly patients [18]. Based
on medication reviews in nursing homes, common drug-
related problems include unnecessary drug use, dose adjust-
ments (especially dose reductions), need for monitoring,
and unclear drug charts [19]. For elderly patients who are
prescribed AEDs, there is an increased risk to experience
DDIs and drug-disease interactions, and particular attention
should be given to both [9, 20].
4.2. The Use of Antiepileptic Drugs. This study demonstrates
that patients in home care services or residing in nurs-
ing homes use AEDs frequently for indications other than
epilepsy. In total 7.8% of the patients in both settings were
prescribed AEDs, which is more than twice as prevalent
(3.4%) as compared to general older Norwegian population
≥65 years [13]. The use of AEDs during the last ten years
also reflects prescribing patterns in other European countries.
Other studies of elderly patients in, for example, German and
US nursing homes, report AED use to vary between 5 and
11% [21, 22], while community-dwelling elderly and elderly
patients in Swedish institutions use 2% and 9%, respectively
[23]. Both the incidence and prevalence, 9.0/1000 in a study
including patients with 18–82 years [24] versus 6.6/1000 in a
study of patients from 0 to 12 years [25], of epilepsy are higher
but stable in older patients compared to younger patients [26–
28].
There were no differences in the use of AEDs between
patients in home care services and nursing homes, except for
two drugs: gabapentin, used more frequently in home care
service patients, and oxcarbazepine, used more frequently in
nursing home patients. Treatment with gabapentin probably
reflects use in neuropathic pain, while oxcarbazepine is
primarily indicated in focal epilepsies [29]. According to
recent updated treatment guidelines, gabapentin and lam-
otrigine have a level A evidence for the treatment of focal
epilepsies in the elderly [30], while there are no studies
at present for oxcarbazepine. It seems reasonable that the
frequent use of oxcarbazepine is an alternative to the most
commonly used AED, carbamazepine, since oxcarbazepine
has no autoinduction or strong enzyme-inducing properties
[9]. Furthermore, the use of older compared to newer AEDs
was similar and did not vary significantly between home care
services and nursing homes. Other studies have reported that
olderAEDs aremore frequently used in the elderly [29], while
pregabalin and gabapentin, both newer agents, are commonly
used in neuropathic pain [31].
Patients who were prescribed AEDs compared to non-
AED users were using CNS-active drugs more frequently, in
linewith studies of higher prevalence of psychiatric comorbid
disorders in patients with epilepsy [29, 32].The high percent-
age of coprescribing of psychotropic drugs with lamotrigine
points to an extensive use in psychiatric indications and
opioid analgesics with gabapentin or pregabalin in treatment
of pain, both consistent with earlier observations in the
Norwegian population [2]. A large Norwegian study includ-
ing more than 445.000 elderly patients reported that 35%
received potentially inappropriatemedications. Asmore than
half of these inappropriate medications were psychoactive
substances [33], elderly AEDusersmay have an increased risk
to experience drug-related problems.
4.3. Antiepileptic Drugs Involved in Other Drug-Drug Interac-
tions. Careful considerations and profound pharmacological
knowledge are necessarywhen combiningAEDs orwhenever
changing AED therapy. The prevalence of DDIs in our study
was 45% within patients using an AED. Most of the AEDs
(i.e., carbamazepine, phenobarbital, and phenytoin) involved
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Table 3: Mechanisms, clinical consequences, severity, and frequencies of pharmacokinetic drug-drug interactions involving antiepileptic






Clinical effects and potential consequences# Severity$ Frequencies
Enzyme inducers
Carbamazepine, n = 189
Enzyme-inducing properties, CYP
3A4, 2C9, 1A2, or UGTs
Benzodiazepines
Decrease in serum concentrations of substrates of




Dose adjustment needed. Decreased serum
concentration of haloperidol by 50% but varies with
dose of carbamazepine.$
B 7
Lamotrigine Dose adjustment needed. Decreased serumconcentration of lamotrigine by 50%. B 6
Amitriptyline Dose adjustment needed. Decreased serumconcentration of amitriptyline by 50–60%.$ B 5
Risperidone
Dose adjustment needed. Serum concentration of
risperidone and active metabolite reduced by 65%
and 50%, respectively.
B 4
Quetiapine Dose adjustment needed. Maximum serumconcentrations of quetiapine reduced by nearly 80%. A 3
Valproic acid
Dose adjustments needed for both drugs.
Carbamazepine concentration increased by 25–50%,
while valproate concentration reduced by 30%.
B 2
Phenobarbital, n = 63
Enzyme-inducing properties, CYP
3A4 or UGT Haloperidol
Dose adjustment needed because of decreased serum
concentration of haloperidol by 50%. B 2
Enzyme inhibitory properties on
CYP 2C19∗ Risperidone
Dose adjustment needed. Increased serum
concentration of risperidone and thus a potential
increase of adverse effects or toxicity.
B 1
Phenytoin, n = 39
Enzyme-inducing properties, CYP
3A4 or UGT Haloperidol
Dose adjustment needed. Decrease in serum
concentrations of substrates of these enzymes and
possibly a decrease in clinical efficacy because of




Valproic acid, n = 93
Enzyme inhibitory properties on
CYP 2C9/19, 3A4?, UGTs
Lamotrigine
Dose adjustment needed because of an increase in
the serum concentrations of substrates of these
enzymes. Clearance of lamotrigine reduced by 50%,





Dose adjustment needed because of decrease of
first-pass metabolism of amitriptyline.





Dose adjustment needed because clearance of




Clinical effects and potential consequences based on Norwegian and Danish interaction databases in addition to a review by Johannessen and Landmark,
2010 [1]. ∗Weak inhibition based on Johannessen and Landmark 2010 [1]. #According to the Danish drug interaction database. $The Norwegian interaction
database (DRUID) denotes severity of drug-drug interactions according to a three-point severity scale: A, should not be combined, B, take precautions, and C,
of academic interest. Herein, only drug-drug interactions in categories A and B are shown. Drug-drug interactions involving the antiepileptic drugs felbamate
(with carbamazepine, diazepam, phenobarbital, phenytoin, and valproic acid), oxcarbazepine (with lamotrigine, phenobarbital, and phenytoin), rufinamide
(with carbamazepine and felbamate), stiripentol (with carbamazepine, felbamate, phenobarbital, phenytoin, and valproic acid), topiramate (>200mg/day with
phenytoin), and valproic acid (with clozapine, imipramine, nortriptyline, and rufinamide) were not identified and therefore not included. ∗∗Duplicates not
shown and not counted.
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Table 4: Other identified drug-drug interactions involving antiepileptic drugs in patients ≥65 years receiving home cares services or living
in nursing homes.
Antiepileptic drugs
Carbamazepine Phenobarbital Phenytoin Valproic acid Pregabalin orgabapentin Total
𝑛 = 189 𝑛 = 63 𝑛 = 39 𝑛 = 93 𝑛 = 278
𝑛 % 𝑛 % 𝑛 % 𝑛 % 𝑛 %
Pharmacokinetic interactions1 79
Amlodipine 19 10.0 4 6.3 23
Atorvastatin 3 4.8 3
Simvastatin 31 16.4 4 10.3 35
Folic acid 5 12.8 5
Zopiclone 9 14.3 4 10.3 13
Pharmacodynamic interactions2 265
Benzodiazepines 4∗ 10.3 49 17.6 53
Fluoxetine 1 1.1 1
Mianserin 13 6.9 2 3.2 2 5.1 17
Opioids 6 9.5 79 28.4 85
Zopiclone 31 16.4 78 28.1 109
Other interactions3 13
AII-blockers and diuretics 13 6.9 13
Interactions in total 107 24 19 1 206 357
1Caused by combination with AED enzyme inducers or inhibitors causing a decrease in serum concentration and lack of efficacy of the affected drug or an
increase in serum concentration and excessive adverse effects or toxicity, respectively. 2With other CNS-active drugs resulting in a possibility for excessive
adverse effects and sedation. 3Increased excretion of sodium and increased risk of hyponatremia with carbamazepine. ∗Also a pharmacokinetic interaction
and included in Table 3.
in DDIs induce the metabolism of other drugs, resulting
in decreased serum concentrations of a large number of
drugs [34, 35]. For instance, zopiclone in combination with
phenobarbital or phenytoin may, due to pharmacokinetic
properties, lead to a reduction in total serum concentration
of zopiclone. Contrarily, zopiclone combined with carba-
mazepine increases sedation, as well as other CNS-depressant
effects, that is, causing a pharmacodynamic interaction.
4.4. Clinical Considerations. This large study of elderly
patients in need of health services obtained detailed informa-
tion of drug use based on a multidose dispensed drug reg-
istry. Comprehensive datasets comprising vulnerable older
patients are difficult to retrieve and are seldom easily avail-
able. For instance, the Norwegian Prescription Registry does
not include patients from nursing homes. Thus, these data
can be especially useful for further clinical assessment of
importance for prescribers and clinical pharmacists consid-
ering rational drug therapy in this patient group. Our study
shows that, quantitatively, the potentials for pharmacokinetic
and pharmacodynamics interactions are highly common
in elderly patients receiving AEDs. DDIs in general may
affect the fine-tuned balance between efficacy and tolerability.
Pharmacokinetic interactions lead to alterations in the serum
concentrations of various other drugs as summarized, but
the individual response and the clinical significance are
difficult to predict. Additionally, pharmacological effects or
adverse effects due to pharmacodynamic interactions make
it even more challenging to predict a treatment outcome
in the individual patient. The combination of several CNS-
active drugs, as well as the possibility of excessive adverse
drug reactions, for example, sedation and impaired cognitive
function, advocates close monitoring. Studies on medication
review in elderly recommend dose adjustments or reducing
the number of CNS-active drugs given concomitantly [19].
Our findings highlight the importance of awareness
of excessive adverse effects or toxicity when giving AEDs
in polytherapy. The increase in total drug load calls for
attention towards pharmacodynamic and pharmacokinetic
drug interactions, which subsequentlymay lead to alterations
of effects and adverse drug reactions. Conversely, ending
drug treatment could also lead to adverse drug reactions as
a result of ongoing DDI processes [1]. Therefore, clinicians
should be aware of drug combinations with susceptibility of
serious clinical outcomes. For instance, it is important with
strategies to avoid combinations including carbamazepine,
phenobarbital, or phenytoin, particularly since these drugs
often cause therapeutic failure with other drugs if they were
not dosage-adjusted. It is also important to systematically
reconsider and decrease the dosage of all CNS-active drugs
to minimize adverse effects and take into account pharma-
cokinetic changes, that is, absorption, distribution, and elim-
ination alterations, with increasing age, in particular, since
elderly patients demonstrate even more extensive variability
in pharmacokinetics than younger adults [9, 36]. AEDs that
are often used in this patient group, and as the present results
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prove, include gabapentin and pregabalin, where extensive
variability in serum concentration versus dose ratios recently
was shown [37]. Based on the present results we recommend
that all elderly people receiving care services should have the
possibility of having their medications reviewed by pharma-
cists at regular intervals to limit the number of drugs and
ensure that DDIs are prevented. Furthermore, there should
be a concerted effort to replace older AEDs with newer AEDs
in this population to avoid the risk of interactions caused
by enzyme-inducing AEDs (carbamazepine, phenytoin, and
phenobarbital). Finally, therapeutic drug monitoring should
be included as a standard of care for all elderly patients
receiving AEDs.
4.5. Strengths and Limitations. A major strength of this
study is the large number of patients included representing
approximately 30% of all patients receiving multidose dis-
pensed drugs in Norway in 2009. Since there are no registries
where these elderly patients are included, detailed studies
regarding their use of drugs in real life are often difficult to
conduct. The representativeness could have been improved
by including patients from the other twomultidose dispensed
drug suppliers. However, we do not have any indications that
the selected supplier differs with regard to patient population.
Prescribing patterns might differ when it comes to multidose
dispensed drugs versus ordinary drug dispensing, as the
system does not seem to reduce the number of errors in
transferring data aboutmedication between health care levels
[38].
This large study population gives the opportunity to gain
information on drug utilization in a new way, and we could
quantify the actual number of AEDs and other CNS-active
drugs in use and point to the risk of interactions between
these drugs. The large number of possible interactions that
may occur and the fact that this is a risk factor in 45% of the
patients point to a need for careful clinical considerations in
the individual patient and observations with focus on adverse
effects by health care professionals.
We included 10% of the total elderly population receiving
home care services and nursing homes, thus reflecting AED
use in older persons in these two care settings. However,
comparison with other studies is hampered as we used
multidose dispensed drug data. For instance, information
regarding “as required” medications and other formulations
than capsules and tablets was not available (e.g., not includ-
ing rectal administration of diazepam) and thus was not
included in the analyses. Although the data were collected
retrospectively, there are no indications that large changes in
prescriptions of AEDs in the elderly have occurred since data
collection. Another limitation concerns the lack of diagnostic
and clinical data at the individual level. However, regardless
of indication, the risk ofDDIs is of importance formostAEDs
and is often considered clinically relevant.
5. Conclusions
In a large population of elderly, home care service andnursing
home patients do not differ with respect to exposure of
AEDs, but they use more AEDs as compared to the general
population of similar age. The risk of DDIs with AEDs and
other CNS-active drugs should be taken into consideration
and individual clinical evaluations were assessed in this
population. The use of older versus newer AEDs was similar
and did not vary significantly between the two settings. The
fact that 45% of the patients had potential DDIs involving
AEDs and other CNS-active drugs stresses the need for
cautiousness when initiating new therapy and for regular
medication reviews to assess the need for dose adjustments
or deprescribing in elderly. In total the potentials for 436
pharmacokinetic/dynamic AED interactions were identified.
These findings call for close monitoring in the individual
patient to avoid excessive adverse effects or toxicity reactions.
This is an important concern for prescribers and clinical
pharmacists when considering rational therapy in the elderly.
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